Who is sponsoring NCT02732392?

NCT02732392 is sponsored by Assistance Publique Hopitaux De Marseille.

What drugs are being tested in NCT02732392?

Interventions in NCT02732392: standard lymphadenectomy, lymphadenectomy radio-isotope method.

What condition does NCT02732392 study?

NCT02732392 studies Patient With Prostate Cancer.

Is NCT02732392 still recruiting?

NCT02732392 is currently completed. Last updated 24 May 2023.

Last reviewed 2023-05-24 · How we verify

NCT02732392: SENTINELLE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer

Completed NA Last updated 24 May 2023

What this trial tests

NA trial testing standard lymphadenectomy in Patient With Prostate Cancer in 177 participants. Completed in 7 April 2023.

Timeline

9 January 2013

Primary endpoint
19 March 2019

7 April 2023

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	177
Start date	9 January 2013
Primary completion	19 March 2019
Estimated completion	7 April 2023
Sites	1 location across France

Drugs / interventions tested

standard lymphadenectomy
lymphadenectomy radio-isotope method

Conditions studied

Patient With Prostate Cancer — all drugs for Patient With Prostate Cancer →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, male only, with Patient With Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The diagnosis of a ganglionic infringement(achievement) at a patient reached (affected) by a prostate cancer is a factor(mailman) of bad forecast. The locoregional ganglionic staging is a very important element in the coverage (care). He allows to determine the local extension of the disease and the type(chap) of therapeutics to implement(operate) after the surgery. The standard cleaning out at present recommended by the European company (society) of urology at the patients at intermediate or high risk of second offense (recurrence) after local treatment(processing), has to concern the obturating pit, the internal and external iliac territories. However this type(chap) of cleaning out does not seem to solve all the problems of locoregional stratification. Indeed, several studies concerning the radio-controlled cleaning out highlighted that 10 in 30% of ganglions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radioisotope-guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients With Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).
Lannes F, Baboudjian M, Ruffion A, Rouy M, et al · · 2023 · cited 11× · PMID 36331157 · DOI 10.1097/ju.0000000000003043

Verify or expand the search:

Other trials of standard lymphadenectomy

Trials testing the same drug.

NCT03081351 — Extended Retroperitoneal Lymphadenectomy and Nerve Plexus Clearance Versus Standard Lymphadenectomy in Pancreaticoduoden · NA · unknown

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02732392 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
Last refreshed: 24 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02732392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing